Anti-S1P [LT1009], Human IgG1, Fc Silent™, kappa
Catalogue Number: AB05086-10.3-BT-ABA
| Manufacturer: | Vector Laboratories, Inc (ABA) |
| Type: | Recombinant Monoclonal |
| Alias: | Sonepcizumab; sphingosine-1-phosphate |
| Shipping Condition: | Blue Ice |
| Unit(s): | 1 mg |
| Host name: | Human |
| Clone: | LT1009 |
| Isotype: | IgG1 |
| Immunogen: | The original antibody was generated by grafting the CDR loops of the murine parent antibody (306D) onto a human IgG1K isotype framework. 306D was generated by immunizing mice with S1P. |
| Application: | ELISA, InVitroA, InVivoA, SPR, Crstion |
Additional Text
Purification
Purified
Antibody Clonality
Recombinant Monoclonal
Storage Note
Store at 4⁰C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommed this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20⁰C.
Short Description
This is a reformatted human IgG1 Fc Silent Fc Silent™ antibody, based on the original human IgG1 format, created for improved compatibility with existing reagents, assays and techniques.
Application Notes
The antibody blocked S1P-mediated release of the pro-angiogenic and prometastatic cytokine, interleukin-8, from human ovarian carcinoma cells using an in vitro bioassay (IC50= 374). The antibody demonstrated robust anti-angiogenic activity in the choroidal neovascularization (CNV) model of age-related macular degeneration (AMD) as well as disruption of lymphocyte trafficking when given intravenously (O'Brien et al., 2009; PMID: 19509417). The crystal structure of the Fab format of the antibody in complex with S1P was determined. The specificity of the IgG1 format of the antibody for S1P was confirmed by ELISA analysis. The Fab format of the antibody showed a binding affinity (KD) for S1P of 130 nM or 1.1 nM in the absence or presence of Ca2+ (Wojciak et al., 2009; PMID: 19815502). The original format of the antibody significantly reduced vascular leakage following laser rupture of bruch's membrane. The original format of the antibody was able to retard the progression of human colorectal (COLO0205) carcinoma tumors grafted subcutaneous (sc) and established in female Ncr (nu/nu) mice when used in combination with other anti-cancer agents (Avastin 48% and Paclitaxel 100%). The original format of the antibody in combination with Avastin showed a tumor reduction of 41% of human HT29 colon tumor xenografts implanted sc in female athymic NCr-nu/nu mice (US8067549B2).
AB05086-10.3-BT Datasheet
SUPPORT
outstanding technical support
PRODUCT
we offer a full product guarantee
DELIVERY
we offer free delivery to UK universities and non profit organisations